Key facts
- L'Oreal's brands SkinCeuticals and Kiehl's have products designed to address skin sagging related to GLP-1 use.
- L'Oreal increased its stake in dermatology firm Galderma to 20% in December.
L'Oreal, the beauty giant behind brands like Maybelline and La Roche-Posay, has reported a 7.7% increase in sales for the three months ending September, surpassing analyst expectations. CEO Nicolas Hieronimus noted that the growing popularity of weight loss drugs, known as GLP-1s, is significantly affecting beauty and skin care consumption. He stated that L'Oreal's brands, including SkinCeuticals and Kiehl's, are developing products to address side effects such as skin sagging associated with rapid weight loss from these medications. The company also increased its stake in dermatology firm Galderma to 20% in December, with both entities reportedly testing products for GLP-1 users concerned about facial changes.